Esophageal adenocarcinoma (EAC) has increased dramatically in the past 3 decades, making its precursor lesion Barrett’s esophagus (BE) an important clinical problem. Effective interventions are available, but overall outcomes remain…

Barrett’s esophagus is the only identifiable premalignant condition for esophageal adenocarcinoma. Endoscopic eradication therapy (EET) has revolutionized the management of Barrett’s-related dysplasia and intramucosal cancer. The primary goal of EET…

Barrett’s esophagus (BE) is more common in developed countries. Endoscopic therapy is an effective treatment method in management of dysplastic BE. Ablation by thermal energy, freezing, or photochemical injury completely…

A major paradigm shift has occurred in the management of dysplastic Barrett’s esophagus (BE) and early esophageal carcinoma. Endoscopic therapy has now emerged as the standard of care for this…

The prevalence of esophageal adenocarcinoma is increasing dramatically. Barrett’s esophagus remains the most well-established risk factor for the development of esophageal adenocarcinoma. There are multiple clinical, endoscopic, and pathologic factors…

Surveillance of Barrett’s esophagus for preventing death from esophageal adenocarcinoma is attractive and widely practiced. However, empirical evidence supporting its effectiveness is weak. Longer intervals between surveillance examinations are being…

There is substantial interest in identifying patients with premalignant conditions such as Barrett’s esophagus (BE), to improve outcomes of subjects with esophageal adenocarcinoma. However, there is limited consensus on the…

Central obesity is involved in the pathogenesis and progression of Barrett’s esophagus to esophageal adenocarcinoma. Involved are likely both mechanical and nonmechanical effects. Mechanical effects of increased abdominal fat cause…